Private Advisor Group’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-744,513
| Closed | -$2.88M | – | 2536 |
|
|
2024
Q3 | $2.88M | Buy |
744,513
+714,500
| +2,381% | +$1.98M | 0.02% | 734 |
|
|
2024
Q2 | $69.6K | Buy |
30,013
+14,000
| +87% | +$36.2K | ﹤0.01% | 2255 |
|
|
2024
Q1 | $45.2K | Hold |
16,013
| – | – | ﹤0.01% | 2248 |
|
|
2023
Q4 | $50.9K | Sell |
16,013
-4,000
| -20% | -$13.6K | ﹤0.01% | 2160 |
|
|
2023
Q3 | $66K | Buy |
20,013
+6,000
| +43% | +$18.7K | ﹤0.01% | 2007 |
|
|
2023
Q2 | $46.2K | Sell |
14,013
-6,000
| -30% | -$21.2K | ﹤0.01% | 1969 |
|
|
2023
Q1 | $66.2K | Hold |
20,013
| – | – | ﹤0.01% | 1895 |
|
|
2022
Q4 | $72 | Buy |
20,013
+3,000
| +18% | +$19.6K | ﹤0.01% | 1602 |
|
|
2022
Q3 | $151K | Sell |
17,013
-10,000
| -37% | -$83.1K | ﹤0.01% | 1725 |
|
|
2022
Q2 | $208K | Sell |
27,013
-1,000
| -4% | -$8K | ﹤0.01% | 1827 |
|
|
2022
Q1 | $263K | Buy |
+28,013
| New | +$250K | ﹤0.01% | 1745 |
|
|
2020
Q3 | – | Sell |
-13
| Closed | – | – | 3544 |
|
|
2020
Q2 | $0 | Buy |
+13
| New | +$155 | ﹤0.01% | 3939 |
|
|
2015
Q1 | – | Sell |
-665
| Closed | -$238K | – | 1083 |
|
|
2014
Q4 | $238K | Buy |
+665
| New | +$198K | 0.02% | 804 |
|
Private Advisor Group's LUMO Position: Q4 2024 in Review
Private Advisor Group sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2024, closing a stake of 744,513 shares — an estimated $2.88M sold.
Private Advisor Group first reported a position in LUMO in Q4 2014 and held it in 13 quarters. The position peaked at $2.88M in Q3 2024. 0 funds tracked by Wall St. Rank hold LUMO as of Q4 2024.
- Private Advisor Group reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Private Advisor Group sold 744,513 Lumos Pharma, Inc. Common Stock shares in Q4 2024, an estimated $2.88M.
- Private Advisor Group first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2014 and held it in 13 quarters.
- Private Advisor Group's Lumos Pharma, Inc. Common Stock position peaked at $2.88M in Q3 2024.
- 0 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2024.
Based on Private Advisor Group's 13F filing for Q4 2024, filed 3 Feb 2025.